We then used this short-term assay to analyze ABT-199 cytotoxicity in normal peripheral blood mononuclear cells (PBMNCs), mononuclear cells from newly diagnosed BCR-ABL-positive and BCR-ABL-negative B-lineage ALL patients as well as chronic phase CML CD34+ cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.